DERM News & Events

Journey Medical announced that approximately 85% of all commercial lives in the United States now have access to Emrosi after contracting with the third major group purchasing organization, GPO. Emrosi is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi, with expanded payer access anticipated to facilitate further growth in total prescription demand.

Conflicting accounts over the likelihood of U.S. and Iran coming to the negotiating table continue to whipsaw the market.  For the second time this week, investors faded the opening highs on Wednesday following overnight speculation of an impending truce as optimism gave way to caution, particularly in light of reports that more US troops are heading to the Persian Gulf.  Basic Materials shined among the S&P 500 sectors once again while Energy lagged as the market remains leery of retreat in oil prices from tempered supply risk in the event of a more meaningful progress toward de-escalation.In the opening hour of the evening session, S&P e-minis and Nasdaq 100 contracts are both down 0.1%.  In commodities, WTI Crude Oil sits just above $91 per barrel - slightly higher from U.S. trading close.  Precious metals meanwhile are consolidating Wednesday's strong gains - Gold is above $4,500 and Silver is pulling back below $71.50 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Noodles & Companyup 21.0%Navanup 20.3%H.B. Fullerup 0.5%ALSO HIGHER -Hallador Energyup 7.8% after securing 3-year agreement to sell remaining accredited capacityGrocery Outletup 3.5% after insider buyDOWN AFTER EARNINGS -MillerKnolldown 17.7%Worthington Steeldown 12.9%Journey Medicaldown 8.1%Marchexdown 8.1%Celcuitydown 2.9%

Reports FY25 revenue $61.9M, consensus $64.7M. Claude Maraoui, CEO, said, "We delivered a year of meaningful commercial progress, highlighted by the successful launch and rapid uptake of Emrosi(TM), which is driving solid revenue growth and expanding our presence in medical dermatology. Our financial performance continues to strengthen with rising net product revenues, improving gross margins and expense optimization, supported by disciplined investment in our dermatology focused sales infrastructure. Emrosi(TM) achieved strong prescription momentum and broader payer access throughout the year, and its differentiated clinical profile further reinforces our confidence in the product's long-term potential as a key growth driver for our Company. As we look ahead to 2026 and beyond, we remain well-positioned to continue to execute on our strategy, leveraging our commercial platform to drive improving financial performance, and advancing innovative therapies that address important needs for patients with dermatologic conditions, while increasing value for our shareholders."